Canopy Growth (CGC) Cash from Investing Activities (2019 - 2025)
Canopy Growth (CGC) reported Cash from Investing Activities of $15.3 million for Q4 2025, up 1645.86% on a YoY basis from $874704.2 in Q4 2024, and up 3101.35% sequentially from -$508807.3 in Q2 2025.
Canopy Growth (CGC) Cash from Investing Activities (2019 - 2025) Analysis & Trends
Canopy Growth (CGC) has 7 years of Cash from Investing Activities data on file, last reported at $15.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 1645.86% year-over-year to $15.3 million; the trailing twelve-month figure through Dec 2025 stood at $12.1 million (up 157.27% YoY), and the FY2026 full-year result was -$15.6 million, up 53.26% from the prior year.
- Cash from Investing Activities advanced to $15.3 million in Q4 2025, from -$508807.3 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $260.8 million in Q3 2021 to a low of -$438.7 million in Q1 2021.
- A 5-year average of $11.3 million and a median of $6.3 million in 2023 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities plunged 788.29% in 2021 and jumped 1645.86% in 2025, its largest moves.
- Tracing CGC's Cash from Investing Activities over 5 years: stood at -$19.7 million in 2021, then surged by 605.86% to $99.5 million in 2022, then sank by 100.45% to -$448801.2 in 2023, then plunged by 120.11% to -$987871.8 in 2024, then jumped by 1645.86% to $15.3 million in 2025.
- Business Quant data shows CGC's Cash from Investing Activities at $15.3 million in Q4 2025, -$508807.3 in Q2 2025, and -$987871.8 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Canopy Growth | 276.14 Mn | 10.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15.27 Mn |
| Dec 31, 2025 | 15.27 Mn |
| Jun 30, 2025 | -508,807.31 |
| Jun 30, 2025 | -508,807.31 |
| Dec 31, 2024 | -987,871.81 |
| Dec 31, 2024 | -987,871.81 |
| Sep 30, 2024 | -1.63 Mn |
| Sep 30, 2024 | -1.63 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Jun 30, 2024 | -31.58 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Mar 31, 2024 | 12.98 Mn |
| Dec 31, 2023 | -448,801.21 |
| Dec 31, 2023 | -448,801.21 |
| Sep 30, 2023 | 44.86 Mn |
| Sep 30, 2023 | 44.86 Mn |
| Jun 30, 2023 | 106.14 Mn |
| Jun 30, 2023 | 106.14 Mn |
| Mar 31, 2023 | 67.50 Mn |
| Mar 31, 2023 | 67.50 Mn |